Previous Article | Next Article ![]()
Journal of Clinical Microbiology, June 2003, p. 2311-2316, Vol. 41, No. 6
0095-1137/03/$08.00+0 DOI: 10.1128/JCM.41.6.2311-2316.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Wayne M. Sullender,2 A. K. Prasad,3 Lalit Dar,1 and Shobha Broor1*
Department of Microbiology, All India Institute of Medical Sciences, New Delhi,1 Department of Respiratory Virology, VP Chest Institute, Delhi, India,3 Departments of Pediatrics and Microbiology, University of Alabama at Birmingham, Birmingham, Alabama2
Received 26 September 2002/ Returned for modification 9 December 2002/ Accepted 14 March 2003
|
|
|---|
|
|
|---|
Reinfections due to RSV occur throughout life (24, 25), reflecting incomplete immunity to the virus. Children initially infected with a group A RSV are relatively protected against group A infection, and reinfections are more likely to be due to the heterologous group B RSV (19). In addition to major group differences, extensive G protein variations are seen within each group of viruses (4, 24). This intragroup diversity may contribute to the ability of RSV to cause repeated infections. Hospital-based studies from developing countries have documented the importance of RSV as a frequent cause of acute lower respiratory infections, and it is responsible for 27 to 96% of hospitalized cases of acute lower respiratory infections (29). Data on genetic variability among RSV isolates from developing countries are, however, limited.
In India, RSV has been identified as an important cause of lower respiratory tract infections (17 to 32%) in the pediatric age group (12, 15), but there are no reports from India on the molecular epidemiology of RSV. The ability to differentiate RSV into groups and subgroups is useful for epidemiological purposes as well as to assess the role of genetic variations in reinfections. The current study was designed to detect and type RSV by molecular techniques and to assess the contribution of RSV to hospitalizations due to lower respiratory tract infections (pneumonia) in our setting.
|
|
|---|
Virus stocks. Standard strains of RSV group A (A2 strain) and group B (8/60 strain) were grown in HEp-2 cells and titrated by 50% tissue culture infectious dose assays. These stocks were used for standardization of RT-PCR, centrifugation-enhanced cultures, and positive controls in both methods. Uninfected HEp-2 cells were used as a negative control.
Isolation of RSV from nasopharyngeal aspirates with centrifugation-enhanced culture. Virus isolation by centrifugation-enhanced culture on HEp-2 cells was carried out on all 200 clinical specimens. The nasopharyngeal aspirates were inoculated in duplicate onto 24-well tissue culture plates with coverslips (12 mm) containing monolayer of HEp-2 cells. Plates were centrifuged at 1,000 rpm for 1 h and incubated at 33°C in a 5% CO2 atmosphere. At 48 h postinoculation, the viral pathogen was identified by immunofluorescent staining with a blend of monoclonal antibodies to the fusion (F) and attachment (G) proteins (Chemicon Inc.) of RSV. This method has been described earlier by our laboratory; the samples characterized in the previous publication were analyzed by PCR in this investigation (15).
Viral RNA extraction. To standardize the RT-PCR and to determine the sensitivity, tissue culture-grown standard strains (8/60 and A2) of RSV of a known 50% tissue culture infectious dose were taken, and serial log dilutions were made from 10-1 to 10-8. Viral RNA was extracted from 400 µl of tissue culture lysate or clinical samples (nasopharyngeal aspirates) by the guanidinium isothiocyanate method (3) followed by ethanol precipitation. Four units of RNasin (Promega Corp.) and 10 µg (1 µg/µl) of glycogen (Sigma Chemicals) were added to samples prior to RNA extraction. The RNA pellet was vacuum dried and suspended in 10 µl of 0.1% diethyl pyrocarbonate-treated water and used for cDNA synthesis.
Oligonucleotides. The oligonucleotides for external PCR and seminested PCR amplification were selected from conserved regions of the G and F protein genes based on primers described by Sullender et al. (24) as well as published sequences. Primer F164 was used as the antisense primer for both external and seminested PCR. The G32 primer was used to amplify both the genogroups in external PCR, and G267 and G399 were used as internal primers for genogroups A and B, respectively (16). The sequence, location, and specificity of primers were as follows: F164(AS)164-186 (F gene), 5'-GTT ATG ACA CTG GTA TAC CAA CC-3', group A and B; G32(S)10-30 (G gene), 5'-GCA ACC ATG TCC AAA CAC AAG-3', group A and B; G267(S)247-267 (G gene), 5'-GAT GCA ACA AGC CAG ATC AAG-3', group A; and G399(S)378-399 (G gene), 5'-AAT ACA AAA TCA GAA ACA CAC C-3', group B.
cDNA synthesis and PCR amplification. Reverse transcription was performed by taking 2.5 µl of viral RNA in a final volume of 20 µl. The reaction mixture contained RT buffer, 200 U of Superscript RNase H reverse transcriptase (Gibco BRL, Life Technologies), 200 mM deoxynucleoside triphosphate mix, and 200 ng of random primer per µl (PdN6). The reaction mixture was incubated for 90 min at 37°C, followed by 5 min of enzyme inactivation at 95°C.
External PCR amplification was performed by taking 10 µl of cDNA in a final volume of 50 µl. The reaction volume contained 50 pmol each of primers F164 and G32, 200 mM deoxynucleoside triphosphate mix, 2 mM MgCl2, and 2.5 U of Taq polymerase (Gibco BRL, Life Technologies). The reaction was carried out for 32 cycles of amplification (denaturation at 94°C for 1 min, annealing at 55°C for 1.5 min, extension at 72°C for 1.5 min, followed by final extension for 7 min). The amplified product of
1.1 kb was visualized on a 1% agarose gel stained with ethidium bromide.
Seminested PCR.
The diluted external PCR products were used for seminested PCR. Fifty microliters of the final volume of PCR mix contained 2.5 U of Taq polymerase (Gibco BRL, Life Technologies), 1.5 mM MgCl2, 200 mM deoxynucleoside triphosphate mix, and 50 pmol of primer G267 for group A or G399 for group B and antisense primer F164. Amplification for 28 cycles was done with the same PCR profile as used for external PCR. The amplified products of the group A and B RSVs were
0.9 kb and
0.78 kb in length, respectively.
Restriction endonuclease digestion. The seminested PCR amplicons were purified with a Nanosep microconcentrator (Pall Filtron) and subjected to restriction endonuclease digestion with RsaI, PstI, HincII, and AluI enzymes (21). Approximately 0.5 to 1.0 µg of DNA was subjected to digestion, and the fragments were analyzed by electrophoresis in 2.5% agarose gels. Within each virus group, the restriction patterns were assigned letter and number designations to facilitate comparisons among the viruses studied. The first letter of the designation represents the restriction enzyme, the second letter represents the group of RSV, and the number represents the pattern number.
|
|
|---|
Detection and typing of A and B strains of RSV by RT-PCR and seminested PCR. RSV was detected in 21 out of 200 nasopharyngeal aspirates by external PCR. However, by seminested RT-PCR, 45 out of 200 nasopharyngeal aspirates were positive for RSV (Fig. 1). Of these 45, 15 were typed as group A and 29 as group B. In one sample, a presumed dual infection was detected, as both the 0.9- and 0.78-kb bands were visualized and the results were confirmed thrice by repeated testing.
![]() View larger version (36K): [in a new window] |
FIG. 1. (A) Agarose gel showing the results of external RT-PCR on clinical samples (nasopharyngeal aspirates). lane M, X174 HaeIII digest (molecular weight marker); lane 1, negative control; lane 2, positive control; lanes 3 to 7, clinical samples. A band of 1.1 kb is observed in lanes 2, 3, 5, and 7. (B) Agarose gel showing the results of seminested PCR on clinical samples lane M, X174 HaeIII digest (molecular weight marker); lane 1, negative control; lane 2, group A positive control; lane 3, group B positive control; lanes 3 to 9, clinical samples. A band of 0.9 kb of group A RSV is seen in lanes 2, 8, and 9, and a band of 0.78 kb of group B RSV is seen in lanes 3, 5 and 6. No bands were seen in lanes 4, 7, and 10.
|
|
View this table: [in a new window] |
TABLE 1. Comparison of RT-PCR and centrifugation-enhanced culture (CEC) results
|
![]() View larger version (38K): [in a new window] |
FIG. 2. Agarose gel showing restriction enzyme pattern of group A RSV with RsaI, HincII, and PstI enzymes. Panel A (digestion with RsaI): lane M, X174 HaeIII digest (molecular weight marker); lanes 1 and 2, 0.9-kb uncut amplicon and digested amplicon of positive control of group A, respectively, lanes 3 to 6, digested amplicons of group A sample strains. The ra1 pattern was seen in lanes 2 to 5, and the ra2 pattern was seen in lane 6. Panel B (digestion with HincII): lane M, X174 HaeIII digest (molecular weight marker); lanes 1 and 2, 0.9-kb uncut amplicon and digested amplicon of positive control of group A, respectively; lanes 3 to 5, digested amplicons of group A sample strains. The ha1 pattern was seen in lanes 2 to 5. Panel C (digestion with PstI): lane M, X174 HaeIII digest (molecular weight marker); lanes 1 and 2, 0.9-kb uncut amplicon and digested amplicon of positive control of group A, respectively; lanes 3 to 6, digested amplicons of group A sample strains. The pa1 pattern was seen in lanes 2 to 5, and the pa2 pattern was seen in lane 6.
|
![]() View larger version (90K): [in a new window] |
FIG. 3. Agarose gel showing restriction enzyme pattern of group B RSV with RsaI, HincII, PstI, and AluI. Panel A (digestion with RsaI): lane M, X174 HaeIII digest (molecular weight marker); lanes 1 and 2, 0.78-kb uncut amplicon and digested amplicon of positive control of group B, respectively; lanes 3 and 4, digested amplicons of group B sample strains. The rb1 pattern was seen in lanes 2 to 4. Panel B (digestion with HincII): lane M, X174 HaeIII digest (molecular weight marker); lanes 1 and 2, 0.78-kb uncut amplicon and digested amplicon of positive control of group B, respectively; lane 3, digested amplicons of group B sample strain. The hb1 pattern (uncut) was seen in lanes 2 and 3. Panel C (digestion with PstI): lane M, X174 HaeIII digest (molecular weight marker); lanes 1 and 2, 0.78-kb uncut amplicon and digested amplicon of positive control of group B, respectively; lane 3, digested amplicons of group B sample strain. The pb1 pattern (uncut) was seen in lanes 2 and 3. Panel D (digestion with AluI): lane M, X174 HaeIII digest (molecular weight marker), lanes 1 and 2, 0.78-kb uncut amplicon and digested amplicon of positive control of group B, respectively; lanes 3 and 4, digested amplicons of group B sample strains. The ab1 pattern was seen in lanes 2 and 4, and the ab2 (uncut) pattern was seen in lane 3.
|
|
View this table: [in a new window] |
TABLE 2. Restriction enzyme analysis of group A RSV strains
|
|
View this table: [in a new window] |
TABLE 3. Restriction enzyme analysis of group B RSV strains
|
![]() View larger version (7K): [in a new window] |
FIG. 4. Schematic diagram of restriction enzyme patterns of amplicons of seminested PCR. Lane M, øX174 molecular weight markers; ua, undigested amplicon of group A RSV; ra1, restriction endonuclease pattern of group A strains with RsaI; ra2, restriction endonuclease pattern of group A strains with RsaI; ha1, restriction endonuclease pattern of group A strains with HincII; pa1, restriction endonuclease pattern of group A strains with PstI; pa2, restriction endonuclease pattern of group A strains with PstI; ub, undigested amplicon of group B RSV; rb1, restriction endonuclease pattern of group B strains with RsaI; hb1, restriction endonuclease pattern of group B strains with HincII; pb1, restriction endonuclease pattern of group B strains with PstI; ab1, restriction endonuclease pattern of group B strains with AluI; ab2, restriction endonuclease pattern of group B strains with AluI.
|
|
|
|---|
Direct immunofluorescence immunoassay is a rapid technique for identification of respiratory viruses, but it is less sensitive than culture, and negative specimens may need to be confirmed by culture. Centrifugation-enhanced culture is more rapid and sensitive than standard culture (13, 17). RT-PCR provides a sensitive tool for both detection and typing of RSV into groups (6, 8). In addition, PCR products can be further characterized to study RSV molecular epidemiology. The primers F164 and G 32 (24) were used as external primers to amplify RSV strains. In a previous study, the G32 primer was found to be specific for group B RSV (24). In this application for direct detection of viruses in clinical samples, we sought increased sensitivity. Differences from the earlier assay included lowering of the annealing temperature and the inclusion of a random hexamer primer in reverse transcription. However, under these conditions the G32 primer could amplify both group A and B RSV, yielding a product of 1.1 kb. Therefore we used a seminested approach with the specific primers for group A (G267) (24) and B (G399) (16).
RSV was detected in 30 samples by both centrifugation-enhanced culture and RT-PCR; in 15 samples virus was detected by RT-PCR alone; and in four samples centrifugation-enhanced culture detected virus but RT-PCR was negative. The samples which were RT-PCR positive and culture negative might reflect a false-positive result from RT-PCR testing. However, earlier studies with RT-PCR on clinical samples have suggested that RT-PCR may be more sensitive than culture for detection of virus in clinical samples (5, 28). Seminested PCR failed to detect viral RNA in four samples that were positive by centrifugation-enhanced culture. These false-negative results might have occurred for a variety of reasons, including viral genetic variability, degradation of template RNA, or inhibitory substances in the samples (21). A combination of the two techniques was of value in increasing the sensitivity of detection.
Both group A and B RSV were found during the 2-year study period, with a predominance of group B strains. Most of the other studies on prevalence of group A and B RSV have shown predominance of group A viruses (8, 9). Recent studies from developing countries have begun to define RSV disease burden and epidemiology. In Mozambique, as in this study, group B viruses were found to have a higher prevalence than group A viruses (23). In a rural district hospital in Mozambique, RSV was identified in 8.6% of children presenting to the outpatient department with cough or nasal secretions and 10.6% of children admitted to the hospital with lower respiratory infection (14). Involvement of the lower respiratory tract (59.7%) and hospital admission (18.1%) occurred more often than described in developed countries.
When RSV from rural South African clinics were compared to those from hospitalized patients in Soweto, most viruses were not significantly different between the two locations (28). In Gambia, the incidence rate per 100 infants for acute lower respiratory infections was 9.6 cases per year and 0.83 for severe RSV-associated illness. RSV accounted for 19% of all hospital admissions for acute lower respiratory infections (30). The identification of RSV as the etiologic agent of 24.5% of acute lower respiratory infections in our study exceeds that reported above for Mozambique and the Gambia. This may reflect the heightened sensitivity provided by a combination of culture and molecular detection techniques compared to antigen detection by enzyme-linked immunosorbent assay or immunofluorescence in the other studies.
With the screening technique of restriction fragment analysis, genetic heterogeneity was observed among both group A and B RSV. Two composite patterns were observed in both groups. Earlier studies reported less genetic variability among group B viruses compared to group A RSV (8, 24). However, we observed less variability among the group A viruses than described earlier (1, 2, 4) The restriction fragment analysis employed here was used as a screening tool for genetic variability and is not expected to reveal the full extent of genetic differences. Nucleotide sequence analysis of these samples should provide precise determination of the molecular differences among these viruses.
A detailed understanding of the epidemiology of RSV in India will require prospective, longitudinal, and community- and hospital-based investigations combined with more detailed genetic analyses of the circulating viruses. These approaches will provide insight into the role of viral genetic variability in reinfections. This is the first study from the Indian subcontinent on the use of RT-PCR on clinical samples for detection and typing of RSV. This is also the first report on genetic heterogeneity among group A and B RSV from the Indian subcontinent. In this study, we demonstrate that RT-PCR appears to be more sensitive than centrifugation-enhanced cultures for detection of RSV in clinical samples. Future studies of RSV epidemiology in health care settings and in the community will lay a foundation for efforts to define and ultimately reduce the burden of disease due to RSV in India.
Present address: Department of Ophthalmology, Dean A. McGee Eye Institute, Oklahoma University of Health Sciences Center, Oklahoma City, OK. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»